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Abstract 
Purpose: To investigate the therapeutic effect of glucosamine cyclohexyl ester on osteoarthritis (OA) in 
a rat model. 
Methods: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot 
assays were used to analyze the effect of glucosamine cyclohexyl ester on changes in mRNA and 
protein expressions of matrix metalloproteinase and tissue inhibitor of metalloproteinases-1 in isolated 
rat chondrocytes, and in a rat model of OA. The rat model of OA was prepared by injecting 
monoiodoacetate to Sprague-Dawley rats via intra-articular route.  
Results: Treatment of the chondrocytes with glucosamine cyclohexyl ester for 48 h prevented 
interleukin-1 β (IL-1β)-mediated increases in mRNA and protein expressions in matrix 
metalloproteinases-1, -3 and -13, and also blocked IL-1β-induced decreases in mRNA and protein 
expressions of tissue inhibitor of metalloproteinase-1. Glucosamine cyclohexyl ester treatment also 
blocked the onset of morphological changes such as irregular surface, adhesion of tissues and 
presence of osteophytes in the femoral condyle surface of the OA rats. Mankin score for control, OA 
and glucosamine cyclohexyl ester treatment groups were 0.98 ± 0.15, 8.35 ± 0.88 and 2.39 ± 0. 67 (p = 
0.002), respectively. Treatment of OA rats with glucosamine cyclohexyl ester also inhibited increases in 
the activities of matrix metalloproteinases-1, -3 and -13, and decreases of tissue inhibitor of 
metalloproteinase-1 mRNA and protein expressions. Treatment of chondrocytes and OA rats with IL 1β 
caused no significant changes in the levels of H3K27 and H4K8. 
Conclusion:  These results show that glucosamine cyclohexyl ester prevents OA by targeting the 
expressions of matrix metalloproteinases-1, -3 and -13 and tissue inhibitor of metalloproteinases-1.  
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Osteoarthritis (OA) involves the failure of 
chondrocytes to function properly leading to 
degradation of extracellular matrix [1]. 
Chondrocytes are involved in the synthesis of 
extracellular matrix molecules for maintaining the 
stability of the articular cartilage [2,3]. The 
function of chondrocytes is regulated by various 
molecules such as extracellular matrix and 
sulfated proteoglycans through interaction 
between the cells and matrix [4]. The 
development and progression of OA are 
characterized by joint inflammation [5]. 
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Degradation of extracellular matrix molecules 
and inhibition of chondrocyte viability are due to 
the production of oxidants and IL-1β in the 
activated synoviocytes and mononuclear cells 
[6,7]. Studies have revealed that IL-1β induces 
expression of matrix metalloproteinases which 
inhibit the production of extracellular matrix 
molecules in chondrocytes [8,9]. Tissue inhibitors 
of metalloproteinase also enhance the activity of 
matrix metalloproteinases [10]. Disturbance in 
equilibrium between matrix metalloproteinases 
and tissue inhibitors of metalloproteinase leads 
to the development and progression of OA [10]. 
Patients with OA suffer continuously from pain 
and movement disability [11]. 
 
D-Glucosamine (GlcN) naturally present in 
connective and cartilage tissues prevents 
cartilage degradation by normalizing metabolism 
in cartilage and promoting the formation of 
proteoglycans [12]. It regulates the strength of 
cartilage by providing flexibility and elasticity to 
the tissues [12]. These properties have been 
exploited in the use of GlcN for the treatment of 
OA patients [13-15]. It has been reported that 
GlcN modifies various symptoms of OA in 
patients [16]. Indeed, the symptom-modifying 
and relieving effect of glucosamine in the knee of 
OA patients has also been recognized by 
Osteoarthritis Research Society International 
(OARSI) [17].  Studies have shown that GlcN 
treatment suppresses oxidants and IL-8 
expression through its anti-oxidant effects [18].  
 
In the present study, the role of glucosamine 
cyclohexyl ester (a GlcN derivative) in OA 




Reagents and chemicals 
 
Glucosamine was obtained from Wako Pure 
Chemical Industries Ltd. (Osaka, Japan). 
Dimethyl sulfoxide, interleukin-1β, MTT and 
Dulbecco's modified Eagle's medium (DMEM) 
were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). 
 
Synthesis of glucosamine cyclohexyl ester 
 
Glucosamine cyclohexyl ester was synthesized 
from glucosamine in a reaction with cyclohexyl 
iodide in presence of potassium carbonate, with 
tetrahydrofuran as solvent. The reaction mixture 
was refluxed at 80 oC till completion (1 h). The 
end of reaction was indicated by thin layer 
chromatography. The product was then purified 
by silica gel column chromatography and 
characterized using NMR studies. 
Chondrocytes isolation and culture 
 
The rats were acclimatized to the laboratory 
conditions for seven days before starting the 
study. Cartilage was excised from the knee and 
hip joints of the animals. The cartilage was 
digested for 5 h in DMEM with 0.2 % collagenase 
II (Sigma Aldrich). The digest was filtered 
through filter mesh (pore size = 150 µm) and 
subsequently subjected to centrifugation at 300 x 
g for 10 min at 4 ˚C to obtain the chondrocytes. 
The chondrocytes were cultured in DMEM 
medium supplemented with FBS (10 %) at a 
temperature of 37 ˚C. The culture medium also 
contained penicillin (100 U/mL) and streptomycin 
(100 µg/mL). 
 
Determination of effect of glucosamine 
cyclohexyl ether on chondrocyte viability 
 
The chondrocytes were put into 96-well culture 
plates at a density of 5 x 105 cells per well and 
left undisturbed overnight. The chondrocytes 
were then treated with 0.1, 0.2, 0.4, 0.8 and 1.6 
µM of glucosamine cyclohexyl ester for 48 h in 
DMEM medium devoid of serum. Following 
incubation of the chondrocytes, the medium was 
removed and 10 µL of CCK 8 solution added to 
each well. The plates were then incubated for 4 h 
a 37 oC, and the absorbance of each well was 
read three times in a microplate reader (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) at 465 
nm. 
 
Analysis of matrix metalloproteinases and 
tissue inhibitor of metalloproteinases-1 in 
chondrocytes 
 
Into a 6-well culture plate chondrocytes were put 
at a density of 2 x 104 cells per well. After 
achieving 75 % confluence, the chondrocytes 
were subjected to serum deprivation for 24 h, 
and stimulated with interleukin-1β at a 
concentration of 5 ng/mL for 12 h. The 
chondrocytes were then treated with 
glucosamine cyclohexyl ester at doses of 0.1, 
0.2, 0.4, 0.8 and 1.6 µM for 48 h, and cultured. 
Thereafter, the cells were collected for analysis 
of matrix metalloproteinase and tissue inhibitor of 




polymerase chain reaction (RT qPCR) 
 
Reverse transcription quantitative polymerase 
chain reaction (RT qPCR) was used for the 
determination of matrix metalloproteinase and 
tissue inhibitor of metalloproteinase-1 mRNA. 
The chondrocytes and cartilage tissues were 
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treated with TRIzol® reagent (Invitrogen; Thermo 
Fisher Scientific, Inc.) for the extraction of RNAs, 
which were reverse-transcribed to cDNA using 
prime Script-RT reagent kit (Takara Bio, Inc., 
Otsu, Japan). The cDNAs were amplified and 
quantified with qPCR (ABI Prism 7500; Applied 
Biosystems; Thermo Fisher Scientific, Inc.) and 
SYBR Premix Ex Taq (Takara Bio, Inc.).  
 
The procedure for qPCR involved holding for 30 
sec at 95 ˚C, cycling for 5 sec at 95 ˚C, followed 
by 30 sec at 70 ˚C. Forty cycles were performed. 
The primers for matrix metalloproteinase and 
tissue inhibitor of metalloproteinase-1 were 
obtained from Sangon Biotech Co., Ltd. 
(Shanghai, China). For matrix metalloproteinase-
1, the forward and backward sequences were 5'-
GGAACAGATACGAAGAGGAAACA-3' and 5'-
TGTGGGAATCAGAGGTAGAAGA-3' 
respectively; for matrix metalloproteinases-3, the 
forward and backward sequences were 5'-
GCATTGGCTGAGTGAAAGAGAC-3' and 5'-
ATGATGAACGATGGACAGATGA-3' 
respectively; for matrix metalloproteinase-13, the 
sequences were 5'-TGAGAGTCATGCCAACAA 
ATTC-3' and 5'-CAGCCACGCATAGTCATG 
TAGA-3'; for tissue inhibitor of metalloproteinase-




Western blot analysis 
 
The protein expressions of matrix 
metalloproteinases and tissue inhibitor of 
metalloproteinase-1 in chondrocyte and cartilage 
tissues were analyzed using western blot assay. 
Proteins were extracted from the chondrocyte 
and cartilage tissues with lysis buffer (Wuhan 
Boster Biological Technology, Ltd., Wuhan, 
China) for 45 min., and quantified using 
bicinchoninic acid method (Thermo Fisher 
Scientific, Inc.). The protein samples were then 
subjected to sodium dodecyl sulfate-
polyacrylamide gel (SDS) gel electrophoresis at 
115 V for 2 h. The proteins were subsequently 
put onto polyvinylidene difluoride membranes. 
After incubation with primary antibodies overnight 
at a dilution of 1:1000, the membranes were 
washed and incubated for 1 h with horseradish 
peroxidase (HRP)-conjugated secondary goat 
anti-rabbit IgG antibody at a dilution of 1:5000 
(Santa Cruz Biotechnology, Inc; catalog no., sc-
2004) at room temperature. The resultant bands 
were examined using enhanced 
chemiluminescence (ECL; Thermo Fisher 
Scientific, Inc.). Quantity One version 4.6.2 
software (Bio-Rad Laboratories Inc., Munich, 
Germany) was used for densitometry. The 
primary antibodies used were matrix 
metalloproteinase-1(catalog no., BS1229), matrix 
metalloproteinase-13 (catalog no., BS6668; both 
from Bioworld Technology, Inc.), matrix 
metalloproteinase-3 (catalog no., 17, 873-1-AP; 
ProteinTech Group, Inc., Chicago, IL, USA) and 
tissue inhibitor of metalloproteinase-1 (catalog 
no., sc-5538; Santa Cruz Biotechnology, Inc, 




All experimental procedures were conducted 
according to the institutional guidelines and also 
followed the guidelines of National Research 
Council Guide for Care and Use of Laboratory 
Animals [19]. Fifteen (8 male and 7 female) 
Sprague-Dawley rats weighing 190 - 210 g were 
purchased from the Laboratory Animal Center, 
Guangzhou University of Traditional Chinese 
Medicine. The animals were maintained in 
animal center under humidity-controlled 
conditions at 25 ˚C. The rats were allowed 
access to standard laboratory chow and clean 
drinking water ad libitum. The animal 
experiments were performed with approval from 
the Animal Care and Use Committee of 
Guangzhou University of Traditional Chinese 
Medicine. 
 
The rats were assigned randomly to three groups 
(5 per group): normal control, osteoarthritis (OA) 
and treatment group. The rats in OA and 
treatment groups were anesthetized using 
pentobarbital sodium (2 %) and subsequently 
injected with mono iodoacetate intra-articularly 
through the knee joint. Rats in the normal control 
group were given equal volume of normal saline. 
The treatment group of rats were injected 5 
mg/kg of glucosamine cyclohexyl ester 
alternately for one month after one week of 
mono iodoacetate administration through intra-
articular route. The rats were sacrificed by 
cervical dislocation under pentobarbital sodium 




Cartilage samples were excised and treated for 
70 h with paraformaldehyde. The samples were 
subsequently decalcified for 6 h by exposure to 
methanoic acid. The decalcified tissues were 
embedded in paraffin and then sliced into 4 mm 
sections. After heating in boiling xylene the 
sections were treated with Safranin-O stain. 
Mankin score was calculated for the tissue 
sections in accordance with standard protocol 
[20]. 
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Data are presented as mean ± standard 
deviation. Student's t-test was used for the 
comparison of data among various groups. 
Moreover, one-way analysis of variance ANOVA) 
and Dunnett's analysis were used. Differences 





Effect of glucosamine cyclohexyl ester on 
chondrocyte viability 
 
Glucosamine cyclohexyl ester exhibited no 
significant inhibitory effect on the viability of 
chondrocytes up to 0.8 µM (Figure 1). 
 
Effect of glucosamine cyclohexyl ester 
treatment on mRNAs of metalloproteinases 
 
The levels of mRNA expressions of matrix 
metalloproteinases-1, -3 and -13 in chondrocytes 
were increased when the chondrocytes were 
cultured in presence of IL-1β. Culturing of 
chondrocytes in presence of IL-1β led to a 
significant decrease in the expression level of 
tissue inhibitor of metalloproteinase-1 (Figure 2). 
However, treatment of the chondrocytes with 
glucosamine cyclohexyl ester for 48 h reversed 
the effect of IL-1β on the expression of matrix 
metalloproteinases and tissue inhibitor of 
metalloproteinase-1 expression. Results from 
western blot analysis were also consistent with 
those from RT-PCR assay. Glucosamine 
cyclohexyl ester treatment reversed the IL 1β-
induced increases in the protein expressions of 
matrix metalloproteinases-1, -3 and -13. 
Similarly, the IL 1β-induced decrease in the 
tissue inhibitor of metalloproteinase-1 protein 
expression was reversed by glucosamine 
cyclohexyl ester treatment (Figure 2). 
Glucosamine cyclohexyl ester treatment of 
chondrocytes without pretreatment with IL 1β 
promoted the protein expression of tissue 
inhibitor of metalloproteinases-1 without 
influencing the expressions of matrix 
metalloproteinases-1, -3 and -13 protein (Figure 
2). 
 
Glucosamine cyclohexyl ester prevents knee 
joint degeneration in OA rat model  
 
Examination of femoral condyles showed marked 
changes in cartilage morphology such as 
irregular surface, adhesion of tissues and 
presence of osteophytes in the OA rats. 
However, in the control group of rats, the femoral 
condyle surface was normal. Femoral condyle 
surface in the OA rats treated with glucosamine 
cyclohexyl ester also showed no morphological 
changes. The protective effect of glucosamine 
cyclohexyl ester against deleterious changes in 
surface morphology in OA rats was also 
confirmed using Safranin-O staining (Figure 3). 
The cartilage of rats in the control group showed 
markedly degree of Safranin-O staining when 
compared to the OA rats. Prevention of cartilage 
degradation by glucosamine cyclohexyl ester 
treatment in the OA rats was evident in the 
higher level of Safranin-O staining in the treated 
OA rats relative to the OA rats (Figure 3). 
 
Analysis of cartilage histology revealed a 
markedly higher Mankin score in the OA rat 
group when compared to the normal control rats. 
The Mankin scores in control, OA and 
glucosamine cyclohexyl ester treatment groups 
of rats were 0.98 ± 0.15, 8.35 ± 0.88 and 2.39 ± 




Figure 1: Determination of optimal dose of glucosamine cyclohexyl ester using CCK-8 assay. The chondrocytes 
were cultured with 0.1, 0.2, 0.4, 0.8 and 1.6 µM of glucosamine cyclohexyl ester for 48 h. For each of the doses, 
viability measurement was performed in triplicates and data are expressed as mean ± S.D. *p < 0.01 compared 
to control without glucosamine cyclohexyl ester 
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Figure 2: Effect of glucosamine cyclohexyl ester on levels of matrix metalloproteinases-1, -3, and -13; and tissue 
inhibitor of metalloproteinase-1 expressions in chondrocytes. Data are presented as mean ± SD. *p < 0.02 




Figure 3: Effect of glucosamine cyclohexyl ester on cartilage degradation in OA rats. Cartilage degradation after 
glucosamine cyclohexyl ester treatment was examined using Safranin-O stain. The images were captured at a 
magnification of x100 
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Glucosamine cyclohexyl ester affects 
expressions of matrix metalloprotenases-1, -3 
and -13, and tissue inhibitor of 
metalloproteinase-1 in vivo. 
 
Examination of cartilage using RT-qPCR analysis 
showed higher expression of matrix 
metalloproteinases-1, -3 and -13 mRNA in OA 
rats, when compared to control group. The level 
of tissue inhibitor of metalloproteinases-1 mRNA 
in OA rats was significantly reduced relative to 
the control group (p < 0.05; Figure 4). However, 
treatment of OA rats with glucosamine cyclohexyl 
ester significantly reduced the increases in matrix 
metalloproteinases-1, -3 and -13 mRNA 
expression, and decreased levels of tissue 
inhibitor of metalloproteinases-1 mRNA (p < 
0.05). These findings from RT-qPCR analysis 
were consistent with results from western blot 
analysis (Figure 4). 
 
Glucosamine cyclohexyl ester increases 
acetylation levels in chondrocytes and 
cartilage  
 
Glucosamine cyclohexyl ester increased the 
acetylation of H3K27 and H4K8 in chondrocytes 




The present study was performed with the aim of 
investigating the role of glucosamine cyclohexyl 
ester in osteoarthritis treatment. Glucosamine 
cyclohexyl ester increased chondrocyte viability 
and prevented cartilage degradation in the OA 
rat model through targeting the expression levels 
of mRNAs and protein in matrix 
metalloproteinases-1, -3 and -13, and tissue 
inhibitor of metalloproteinase-1. Tissue inhibitor 
of metalloproteinases-1 plays an important role in 
the degeneration of cartilage by promoting the 
expression of matrix metalloproteinases [21]. 
Increases in the level of matrix 
metalloproteinases and down-regulation of tissue 
inhibitor of metalloproteinases-1 promote 
cartilage degradation and inhibit chondrocyte 
viability [21]. 
 
It has been reported that the degradation of 
several components of extracellular matrix such 
as type II collagen, is catalyzed by matrix 
metalloproteinases [22]. Degradation of type II 
collagen by matrix metalloproteinases is a 




Figure 4: Effect of glucosamine cyclohexyl ester on expressions of matrix metalloproteinases-1, -3, and -13; and 
tissue inhibitor of metalloproteinase-1 in OA rats 
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Figure 5: Effect of glucosamine cyclohexyl ester on acetylation of H3K27 and H4K8. The rats were treated with 
glucosamine cyclohexyl ester for 48 h after 12 h of pretreatment with IL-1β and then H3K27 and H4K8 acetylation 
was analyzed using western blot assay 
 
In the current study, glucosamine cyclohexyl 
ester significantly inhibited the expression of 
matrix metalloproteinases-1, -3 and -13 mRNA 
and protein in the chondrocytes of OA rats, when 
compared to untreated OA rats. Glucosamine 
cyclohexyl ester also blocked the IL-1β mediated 
decrease in the levels of tissue inhibitor of 
metalloproteinases-1 mRNA and protein in vitro.  
 
Western blot and RT-PCR assay results showed 
markedly higher levels of matrix 
metalloproteinases and lower level of tissue 
inhibitor of metalloproteinases-1 mRNA and 
protein in the OA rats in vivo. However, treatment 
of the OA rats with glucosamine cyclohexyl ester 
prevented the increase in matrix 
metalloproteinases-1, -3 and -13 expressions, 
and decreased tissue inhibitor of 
metalloproteinases-1mRNA and protein. 
Examination of femoral condyles of the OA rats 
showed marked changes in morphology such as 
irregular surface, adhesion of tissues and 
presence of osteophytes, while the femoral 
condyle surface in the OA rats treated with 
glucosamine cyclohexyl ester showed no 
morphological changes. This is an indication of 
the protective effect of glucosamine cyclohexyl 
ester against OA. This protective effect was 
confirmed by results from Safranin-O staining, 
which showed that glucosamine cyclohexyl ester 
treatment markedly reduced the Mankin score in 




The findings of this study demonstrate that 
glucosamine cyclohexyl ester has immense 
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